Abstracts tagged "Reactive arthritis"

Abstract Number: 2189 • ACR Convergence 2024
Migratory Arthritis in Children: What Besides Rheumatic Fever?
bar goldberg¹, Gil Amarilyo², oded Scheuerman¹, tarek Zuabi³, alina Guz¹, Maayan Ravia¹ and yoel Levinsky¹, ¹schneider medical center, petah tikva, Israel, ²Faculty of Medicine, Tel Aviv University, Tel Aviv; Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, Kibbutz Maggal, HaMerkaz, Israel, ³schneider medical center, petah tikva
Background/Purpose: Migratory Arthritis, a not uncommon presentation in pediatrics, is classically associated with rheumatic fever (RF), although can be the first presentation of other medical…
Abstract Number: 1785 • ACR Convergence 2023
Machine Learning Models Identify Gut Microbiota That Predict Chronicity in Reactive Arthritis
Prakashini MV¹, Soumendu Mahapatra², Krushna Chandra Murmu², Rasmita Mishra², Prasanta Padhan¹, Punit Prasad², Ramnath Misra³ and Sakir Ahmed⁴, ¹Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India, ²Institute of Life Sciences, Bhubaneswar, India, ³Kalinga Institute of Medical Sciences, KIIT University, Lucknow, India, ⁴Kalinga Institute of Medical Sciences, Bhubaneswar, India
Background/Purpose: Reactive arthritis (ReA) is the unique infection-triggered spondyloarthritis (SpA). Undifferentiated peripheral SpA (UpSpA) is similar but without previous infection, or psoriasis or inflammatory bowel…
Abstract Number: 0274 • ACR Convergence 2022
Real-world Utilisation and Switching Between Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in the Australian OPAL Dataset
Sabina Ciciriello¹, Geoffrey Littlejohn², Tamas Treuer³, Kathryn Gibson⁴, Peter Youssef⁵, Paul Bird⁶, Catherine OSullivan⁷, Tegan Smith⁸ and Claire Deakin⁹, ¹Melbourne Health, Melbourne, Australia, ²OPAL Rheumatology Ltd, Melbourne, Australia, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Indianapolis, United States of America, Sydney, Australia, ⁵University of Sydney, Sydney, Australia, ⁶University of New South Wales, Sydney, Australia, ⁷OPAL Rheumatology Ltd, Sydney, Australia, ⁸OPAL Rheumatology Ltd, Geelong, Australia, ⁹OPAL Rheumatology Ltd, Mosman, Australia
Background/Purpose: JAK inhibitors (JAKi) have been a major development in treatment for many patients with RA due to their ability to block multiple cytokine pathways…
Abstract Number: 0772 • ACR Convergence 2022
New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
Carina Soto-Fajardo¹, Angélica Peña Ayala², Fernanda Gonzalez², Paola Flores², Ana Cristina Medina², Araceli Bernal², Carlos Pineda², Olga-Lidia Vera-Lastra³ and Luis Javier Jara Quezada², ¹Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, ²Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, ³Centro Médico La Raza, Ciudad de México, Mexico
Background/Purpose: From January 2021 around 60% of the total population has received at least one dose of any COVID-19 vaccine. A minority of vaccinated individuals…
Abstract Number: 2246 • ACR Convergence 2022
Rheumatoid Arthritis Patient Discordance with Provider Treatment Goals Is Associated with Poorer RA Outcomes
Kelly O'Neill¹, Pamela Sinicrope², Cynthia Crowson³, Kathryne Marks⁴, Rachel Giblon⁵, Elena Myasoedova² and John Davis², ¹Rheumatoid Patient Foundation, Winter Springs, FL, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: We previously reported on themes in rheumatoid arthritis (RA) patients' treatment goals which associated with aspects of rheumatology care such as presence of a…
Abstract Number: 0455 • ACR Convergence 2020
HLA-B27 and Host Immune Response: Lessons from Reactive Arthritis
Sophie Wojcik¹, Davina Morris², Gillian Fitzgerald³, Steve Ramkissoon⁴, Nigil Haroon² and Robert Inman⁵, ¹UHN, Montreal, QC, Canada, ²University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, ⁴UHN, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada
Background/Purpose: The natural history of reactive arthritis (ReA) remains poorly understood. Certain patients with ReA will go on to develop a chronic course while others…
Abstract Number: 12 • 2019 ACR/ARP Annual Meeting
Intraarticular and Circulatory Cytokine Responses to Chlamydia Trachomatis: A Clinical Study in Reactive Arthritis/ Undifferentiated Spondyloarthropathy Patients
Sangita Rastogi¹, Praveen Kumar ², Darshan Bhakuni ³ and Geetika Khanna ⁴, ¹ICMR- National Institute of Pathology, Safdarjung hospital campus, New Delhi- 110 029, India, New Delhi, Delhi, India, ²ICMR- National Institute of Pathology, Safdarjung hospital campus, New Delhi- 110 029, India, Kota, Rajasthan, India, ³Department of Rheumatology and Clinical Immunology, Army Hospital (Research & Referral), Dhaula Kuan, New Delhi- 110 010, India, New Delhi, Delhi, India, ⁴Central Institute of Orthopedics (CIO), Vardhaman Mahavir Medical College (VMMC) & Safdarjung hospital, New Delhi-110029, India, New Delhi, Delhi, India
Background/Purpose: Chlamydia trachomatis-induced reactive arthritis (ReA)/ undifferentiated spondyloarthropathy (uSpA) is an immune-mediated situation where development of disease and maintenance of this pathogen remains elusive. The…
Abstract Number: 271 • 2017 ACR/ARHP Annual Meeting
The Trend of Incidence Rate, Frequency and HLA Phenotype of Reactive Arthritis and Uveitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20-Year, Two-Center Retrospective Study
Yoshinori Taniguchi¹, Satoshi Inotani², Hirofumi Nishikawa², Kosuke Inoue³, Taro Horino², Takashi Karashima⁴, Yasuhiko Yoshinaga⁵ and Yoshio Terada³, ¹Endocrinology, Metabolism,Nephrology and Rheumatology, Kochi University, Kochi, Japan, ²Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, ³Kochi University, Nankoku, Japan, ⁴Urology, Kochi University, Nankoku, Japan, ⁵Kurashiki Medical Center, Kurashiki, Japan
Background/Purpose: Intravesical instillation of Bacillus Calmette-Guerin (iBCG) is used as an effective immunotherapy of bladder cancer. However it may have, as adverse event, a reactive…
Abstract Number: 1312 • 2016 ACR/ARHP Annual Meeting
Incidence of Reactive Arthritis, Uveitis and Conjunctivitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20 Years’ Two-Center Retrospective Study
Satoshi Inotani^1,2,3,4, Yoshinori Taniguchi⁵, Takashi Karashima⁶, Yasuhiko Yoshinaga⁷, Hirofumi Nishikawa⁸, Natsuki Maeda⁹, Shimpei Fujimoto⁸ and Yoshio Terada¹⁰, ¹internal medicine, Chikamori Hospital, Kochi, Japan, ²Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi medical school, Nankoku, Japan, ³Urology, Kochi medical school, Nankoku, Japan, ⁴Rheumatic Disease Center, Kurashiki Medical Center, Kurashiki, Japan, ⁵Endocrinology, Metabolism,Nephrology and Rheumatology, Kochi University, Kochi, Japan, ⁶Urology, Kochi University, Nankoku, Japan, ⁷Kurashiki Medical Center, Kurashiki, Japan, ⁸Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, ⁹Endocrinology,Metabolism,Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, ¹⁰Kochi University, Nankoku, Japan
Background/Purpose: To evaluate the incidence of reactive arthritis (ReA), uveitis and conjunctivitis in Japanese patients with bladder cancer following intravesical BCG therapy (iBCG). Methods: The…
Abstract Number: 693 • 2015 ACR/ARHP Annual Meeting
Clinical and Imaging Features of Reactive Arthritis in Guatemala City
Helga Raquel Garcia Ferrer¹, A Garcia Kutzbach², Isa Iraheta³, Jose U. Scher⁴, Joan Von Feldt^5,6 and Alexis Ogdie-Beatty⁷, ¹Society for Worldwide Med Exchange, North Bay Village, FL, ²Internal Medicine, Rheumatology Unit (AGAR), Francisco Marroquin University, School of Medicine, Guatemala City, Guatemala, ³Rheumatology, Guatemalan Association against Rheumatic Diseases (AGAR), Guatemala City, Guatemala, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Philadelphia VA Medical Center, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Reactive arthritis (ReA) is an inflammatory arthritis that typically follows infection. The objectives of this study were to describe the joint and enthesial involvement…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].